|
|
|
| Hepatocellular carcinoma: Current situation and challenge |
| Zhao Li a , b , c , Ji-Ye Zhu a , b , c , ∗ |
a Department of Hepatobiliary Surgery, Peking University People’s Hospital, Beijing 100044, China
b Peking University Institute for Organ Transplantation, Beijing 100044, China
c Beijing Key Laboratory of Liver Cirrhosis and Liver Cancer, Beijing 100044, China
∗ Corresponding author at: Department of Hepatobiliary Surgery, Peking University People’s Hospital, Beijing 100044, China.
E-mail address: gandanwk@vip.sina.com (J.-Y. Zhu).
|
|
|
|
|
Abstract Hepatocellular carcinoma (HCC) ranks the fourth cause of cancer-related death worldwide [1] . More than 50% newly diagnosed HCC patients are in China, while 70% of them are at advanced stage when they are diagnosed [2] . These patients have lost the opportunity of radical surgery and can only receive palliative care. Currently, the modality for these advanced stage HCC patients mainly include: targeted therapy, interventional therapy, chemotherapy, radiotherapy, and immunotherapy.
|
|
|
|
|
|
|
|
|
2019, Vol. 18 
